Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

BACKGROUND: The purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain. METHODS: Societal costs were estimated by collecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lister, Johanna, Stanisic, Sanja, Kaier, Klaus, Hagist, Christian, Gultyaev, Dmitry, Walzer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469277/
https://www.ncbi.nlm.nih.gov/pubmed/23071397
http://dx.doi.org/10.2147/CEOR.S34188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469277/
https://www.ncbi.nlm.nih.gov/pubmed/23071397
http://dx.doi.org/10.2147/CEOR.S34188

Ejemplares similares